- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02298985
Curcumin Addition to Antipsychotic Treatment in Chronic Schizophrenia Patients
Curcumin as add-on to Antipsychotic Treatment in Chronic Schizophrenia Patients: A Randomized, Double-Blind, Placebo-controlled Study
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Design This is a 24-week, randomized, double-blind, placebo-controlled investigation of 40 chronic schizophrenia patients.
Participants Forty patients will be drawn from the patient population of Be'er Sheva Mental Health Center. Recruitment period will last over 2 years.
Patients will be required to have a primary diagnosis of chronic schizophrenia as defined in DSM-IV with predominantly persistent negative signs.
The study will commence only after approval by the local Institutional Ethics Review Board ("Helsinki Committee"). Only willing subjects and able to provide written informed consent, after receiving a comprehensive explanation of the study procedures, will be included in the study. Confidentially will be ensured by means of a number coding system, and all completed research forms will be stored in secure areas.
Procedure Patients will continue receiving their regular antipsychotic medication. The dose will be kept constant for at least 3 months prior to entry and throughout the study period. Curcumin is provided as Curcumin Forte ® (Solgar Israel SupHerb). Circumin capsules are supplied as an 1000 mg soft gelatin capsule for three daily oral administration with meals. At entry patients will receive curcuma capsules (3000 mg/day, three capsules) or placebo in identical capsules in a randomized, double blind mode for 24 weeks: 20 patients will receive curcumin, and 20 patients - placebo.
Participants will be assessed at baseline and after 4, 8, 12, 16 and 24 weeks of treatment. In a case of treatment discontinuation for 24-week of the trial, patients will be followed until end of study period.
Outcome variables will be evaluated by scoring the severity of symptoms (positive, negative, and etc.), and side effects. In addition, liver function tests and a blood cell count will be monitored at baseline and during the study.
For analyzing the results, within-subject pre- and post-treatment responses would be subject to statistical procedures to evaluate whether curcumin can ameliorate the persistent negative symptoms in schizophrenia.
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
-
Beersheva, Israel
- Beersheva Mental Health Center
-
Tirat Carmel, Israel, 84170
- Tirat Carmel Mental Health Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age 18-60 years, male or female
- DSM-IV criteria for schizophrenia.
- Ability and willingness to sign informed consent for participation in the study
- SANS (Scale of Negative Symptoms of Schizophrenia ) > 30 points
- Fixed antipsychotic dosages at least 3 months
- Steady mental state of patients at least 3 months
Exclusion Criteria:
- Current substance use disorder except nicotine dependence
- Regular use of NSAID (non-steroidal anti-inflammatory drugs)
- Cancer history
- Untreated or severe hypertension
- Poorly controlled diabetes mellitus Type I or Type II
- Chronic liver & gallbladder diseases
- Recent GERD (Gastroesophageal Reflux Disorder)
- Neurological disorders: epilepsy, stroke
- Hamilton Depression Scale Hamilton Depression Rating Scale (HAM-D-17 item) > 24 points
- Patients with a known hypersensitivity to curcumin
- Pregnant women or a woman who intends to become pregnant
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Single Group Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: curcumin
curcumin 3 g/day for 6 months
|
3 g/day (3 capsules/day) for 6 months
Other Names:
3 g/day (3 capsules/day) for 6 months
Other Names:
|
Placebo Comparator: placebo
curcumin 3 g/day for 6 months
|
3 g/day (3 capsules/day) for 6 months
Other Names:
3 g/day (3 capsules/day) for 6 months
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Positive and Negative Symptoms Scale (PANSS)
Time Frame: up to 24 weeks
|
baseline and every week 4 up to 24 weeks
|
up to 24 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Clinical Global Impression - Improvement (CGI-I)
Time Frame: up to 24 weeks
|
baseline and every week 4 up to 24 weeks
|
up to 24 weeks
|
Clinical Global Impression - Severity of Adverse Events (CGI-SAE)
Time Frame: up to 24 weeks
|
baseline and every week 4 up to 24 weeks
|
up to 24 weeks
|
Calgary Depression Scale for Schizophrenia (CDSS)
Time Frame: up to 24 weeks
|
baseline and every week 4 up to 24 weeks
|
up to 24 weeks
|
Collaborators and Investigators
Sponsor
Collaborators
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Mental Disorders
- Schizophrenia Spectrum and Other Psychotic Disorders
- Schizophrenia
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Central Nervous System Depressants
- Peripheral Nervous System Agents
- Enzyme Inhibitors
- Analgesics
- Sensory System Agents
- Anti-Inflammatory Agents, Non-Steroidal
- Analgesics, Non-Narcotic
- Anti-Inflammatory Agents
- Antirheumatic Agents
- Antineoplastic Agents
- Tranquilizing Agents
- Psychotropic Drugs
- Curcumin
- Antipsychotic Agents
Other Study ID Numbers
- VLJB-14
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chronic Schizophrenia
-
University of Maryland, BaltimoreCompleted
-
Hôpital le VinatierNantes University Hospital; Centre Hospitalier Henri Laborit; University Hospital... and other collaboratorsCompletedChronic SchizophreniaFrance
-
Queen's UniversityWalmartCompletedChronic SchizophreniaCanada
-
Manhattan Psychiatric CenterNational Institute of Mental Health (NIMH); Albert Einstein College of MedicineUnknownChronic SchizophreniaUnited States
-
All India Institute of Medical Sciences, BhubaneswarRecruitingChronic SchizophreniaIndia
-
TsaoTun Psychiatric Center, Department of Health...RecruitingChronic SchizophreniaTaiwan
-
Rongjun Hospital of Hebei Province Affiliated to...Completed
-
Northwell HealthCompletedChronic SchizophreniaUnited States
-
Newron Pharmaceuticals SPACompletedChronic SchizophreniaUnited States, India
-
SunovionCompletedChronic SchizophreniaUnited States, Colombia, India, Ukraine, Russian Federation, Romania
Clinical Trials on Curcumin
-
H.K.E.S's S.Nijalingappa Institute of Dental Science...Unknown
-
Université de SherbrookeUnknown
-
Kaiser PermanenteCompletedIrritable Bowel SyndromeUnited States
-
Daniel DobererCompleted
-
Federico II UniversityCompleted
-
Gary MorrowNational Cancer Institute (NCI)CompletedPain | Breast Carcinoma | Stage 0 Breast Cancer | Radiation-Induced DermatitisUnited States
-
Woodbury, Michel, M.D.Lawson Health Research InstituteCompletedDepression | Schizophrenia | Schizoaffective DisorderPuerto Rico
-
Emory UniversityCompletedUterine Cervical DysplasiaUnited States
-
University of North Carolina, Chapel HillColgate PalmoliveCompletedHalitosisUnited States
-
Louisiana State University Health Sciences Center...TerminatedMild Cognitive ImpairmentUnited States